1. Home
  2. IMNM vs HRMY Comparison

IMNM vs HRMY Comparison

Compare IMNM & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.42

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$39.01

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
HRMY
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
IMNM
HRMY
Price
$19.42
$39.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
9
Target Price
$26.89
$51.33
AVG Volume (30 Days)
1.2M
769.8K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.44
EPS
N/A
3.17
Revenue
$9,679,000.00
$825,944,000.00
Revenue This Year
N/A
$23.11
Revenue Next Year
N/A
$16.15
P/E Ratio
N/A
$12.25
Revenue Growth
N/A
21.13
52 Week Low
$5.15
$25.52
52 Week High
$20.46
$40.93

Technical Indicators

Market Signals
Indicator
IMNM
HRMY
Relative Strength Index (RSI) 60.95 76.71
Support Level $16.81 $32.77
Resistance Level $20.46 $40.00
Average True Range (ATR) 1.20 1.23
MACD 0.03 0.32
Stochastic Oscillator 72.74 86.72

Price Performance

Historical Comparison
IMNM
HRMY

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: